Skip to main content
. 2022 Mar 28;45(4):769–781. doi: 10.1002/jimd.12496

FIGURE 2.

FIGURE 2

Total plasma glycoprofiling of several high‐mannose N‐glycans for subtyping of Group 2 (ALG3‐, MPDU1‐, DPM1‐, DPM3‐, SRD5A3‐, DOLK‐, RFT1‐, ALG11‐, ALG13‐, PMM2‐, MPI‐congenital disorders of glycosylation [CDG], and hereditary fructose intolerance [HFI]), Group 3 (ALG12‐ and ALG9‐CDG), and Group 4 (CDG‐I defects other than Groups 1–3). High relative abundance of Man3 glycan (A) and Man4 glycan (B) in CDG‐I with mannosylation defects including Groups 2 and 3, as compared with Control and Group 4; (C) further ratio analysis of relative abundances of Man3/Man4 glycans allow discrimination of Groups 2 and 3; (D) analysis of the Man3/Man5 ratio could be used to differentiate Group 2.1 (ALG3‐, MPDU1‐, and DPM1‐CDG) and Group 2.2 (DPM3‐, SRD5A3‐, DOLK, RFT1‐, ALG11‐, ALG13‐, PMM2‐, MPI‐CDG, and HFI); and (E) the relative abundance of Man7/Man8 glycans can be used as diagnostic glycoprofile for ALG12‐ and ALG9‐CDG (Group 3)